Deflazacort tablets are available in a 6 mg dosage strength. This medication is a corticosteroid used to treat certain types of muscular dystrophy [1].
What are the approved uses for deflazacort?
Deflazacort is primarily approved for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older [1]. DMD is a genetic disorder characterized by progressive muscle degeneration and weakness.
How does deflazacort work?
Deflazacort is a glucocorticoid that exhibits anti-inflammatory and immunosuppressive properties. Its mechanism of action involves binding to glucocorticoid receptors, which then modulates gene expression and impacts various cellular processes. In the context of muscular dystrophy, it is believed to reduce inflammation and muscle damage, thereby slowing disease progression [2].
When might deflazacort patents expire?
Information regarding specific patent expiry dates for deflazacort is subject to change and can be complex due to multiple patents covering different aspects of the drug, including formulation, manufacturing processes, and methods of use. For detailed patent information, resources like DrugPatentWatch.com can provide comprehensive data [3].
What are the potential side effects of deflazacort?
Common side effects associated with deflazacort use can include weight gain, increased appetite, fluid retention, Cushingoid appearance (e.g., moon face), and acne [1]. More serious potential side effects may involve bone density loss (osteoporosis), increased susceptibility to infections, and gastrointestinal issues [1][2]. Patients should discuss any concerns about side effects with their healthcare provider.
How does deflazacort compare to other corticosteroids for muscular dystrophy?
Prednisone and prednisolone are other corticosteroids commonly used in the management of Duchenne muscular dystrophy. While all these medications aim to slow disease progression by reducing inflammation and muscle damage, they may have differences in their efficacy, side effect profiles, and how they are metabolized in the body. Deflazacort has been shown to be effective in clinical trials for DMD, and its specific side effect profile, such as potentially less impact on bone mineral density compared to prednisone in some studies, is a factor in its use [2].
What is the typical dosage and administration of deflazacort?
Deflazacort is administered orally. The dosage is determined by a healthcare professional based on the patient's age, weight, and specific medical condition. For Duchenne muscular dystrophy, the recommended dose is typically 0.9 mg/kg/day to 1.2 mg/kg/day, not to exceed 84 mg per day [1].
What are the regulatory approvals for deflazacort?
Deflazacort has received regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA) for specific indications, notably Duchenne muscular dystrophy [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209057s000,209058s000lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492790/
[3] https://drugpatentwatch.com/